COMP <GO>
IOVA vs TARS // FORWARD P/E MULTIPLE
Iovance Biotherapeutics Inc. (NASDAQ) VS. Tarsus Pharmaceuticals Inc. (NASDAQ) • 15-METRIC TALLY: IOVA 1
— TARS 8
■ METRIC PARITY
LAST: $9.56 (-35.45%) • MKT CAP: $4.33B
forward-pe
33.0x
LAST: $74.20 (+2.98%) • MKT CAP: $3.66B
forward-pe
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (IOVA VS. TARS)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | IOVA | TARS | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 34.30% | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -24.10% | -10.90 | TARS | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -7.76% | -0.61% | -7.15 | TARS | /fcf-yield <GO> |
| Operating Margin | -60.00% | -15.70% | -44.30 | TARS | /operating-margins <GO> |
| Net Profit Margin | -60.00% | -14.60% | -45.40 | TARS | /net-margins <GO> |
| Revenue Growth (YoY) | 60.60% | 146.70% | -86.10 | TARS | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 7.08 | 10.19 | -3.11 | TARS | /balance-sheet <GO> |
| Piotroski F-Score Quality | 4/9 | 5/9 | -1.00 | TARS | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 36.8 | 53.4 | -16.60 | TARS | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.99 | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple ACTIVE | 33.0x | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $4.33B | $3.66B | $672.1M | IOVA | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | IOVA REV | TARS REV | IOVA GROSS % | TARS GROSS % | IOVA FCF | TARS FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $263.5M | $451.4M | 34.3% | — | -$336.2M | -$22.3M |
| FY 2024 | $164.1M | $183.0M | 43.2% | — | -$364.0M | -$84.6M |
| FY 2023 | $1.2M | $17.4M | — | — | -$361.9M | -$117.5M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
IOVA // BETA 0.99
TARS // BETA —